Interactions Between Anti-Infective Agents and Immunosuppressants in Solid Organ Transplantation

Trofe‐Clark, Jennifer; Lemonovich, Tracy L.

doi:10.1111/ajt.12123

Cited by 50 publications

(34 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One particularly challenging drug interaction occurs because patients who are on calcineurin and/or mTOR inhibitors are typically at high risk for IFI and often require treatment with triazoles. By inhibiting the clearance of immunosuppressive agents, triazoles can cause accumulation of the immunosuppressive agent and prolonged immunosuppression 25 Individual azoles have varied drug interactions based on their individual binding affinity for the CYP450 isozymes. For example, azole-induced QT interval prolongation is of significant clinical concern.…”

Section: Azolesmentioning

confidence: 99%

New facets of antifungal therapy

et al. 2016

View full text Add to dashboard Cite

Invasive fungal infections remain a major cause of morbidity and mortality in immunocompromised patients, and such infections are a substantial burden to healthcare systems around the world. However, the clinically available armamentarium for invasive fungal diseases is limited to 3 main classes (i.e., polyenes, triazoles, and echinocandins), and each has defined limitations related to spectrum of activity, development of resistance, and toxicity. Further, current antifungal therapies are hampered by limited clinical efficacy, high rates of toxicity, and significant variability in pharmacokinetic properties. New antifungal agents, new formulations, and novel combination regimens may improve the care of patients in the future by providing improved strategies to combat challenges associated with currently available antifungal agents. Likewise, therapeutic drug monitoring may be helpful, but its present use remains controversial due to the lack of available data. This article discusses new facets of antifungal therapy with a focus on new antifungal formulations and the synergistic effects between drugs used in combination therapy.

show abstract

Section: Azolesmentioning

confidence: 99%

New facets of antifungal therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Echinocandins do not concentrate in the urinary tract and are therefore less effective in treating candidal UTI [8]. If fluconazole (or any other triazole) is used, interaction with calcineurin inhibitors (CNI) and mTOR-inhibitors (mTORi) results in significant elevation of CNI / mTORi levels, necessitating dose reduction and careful monitoring of levels and renal function during and after therapy [9].…”

Section: Urinary Tract Infectionsmentioning

confidence: 99%

Infections After Kidney Transplantation: The Bug Bear Of Kidney Transplantation In Tropics

Basu¹

2015

TOUNJ

View full text Add to dashboard Cite

Abstract:Infections are the bugbear of kidney transplantation in the tropics, being responsible for majority of the deaths. Despite the several challenges posed by infections in kidney transplant recipient in the tropics, various developments have resulted in a decline in the rate of infections as well as their consequences. This review aims to be a basic overview of the common infections in KTR with an attempt to provide a unique tropical country perspective.

show abstract

“…Bu durum RTx alicilarinda sik gözlenen antimikrobiyal ilaç direncini akla getirmektedir (23) . Bilindiği gibi terbinafin direnci azol grubu antifungallere göre daha yüksek orandadir, (24) ancak azol derivelerinin kalsinörin inhibitörleri ile olan ciddi ilaç etkileşimi (25) pratikte RTx alicilarinda terbinafin grubunun daha çok yeğlenmesine yol açmaktadir.…”

Section: Discussionunclassified